Cardiol Therapeutics Inc Class A - Asset Resilience Ratio
Cardiol Therapeutics Inc Class A (CRDL) has an Asset Resilience Ratio of 90.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Cardiol Therapeutics Inc Class A strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Cardiol Therapeutics Inc Class A's Asset Resilience Ratio has changed over time. See CRDL net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Cardiol Therapeutics Inc Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cardiol Therapeutics Inc Class A market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$21.42 Million | 90.67% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$21.42 Million | 90.67% |
Asset Resilience Insights
- Very High Liquidity: Cardiol Therapeutics Inc Class A maintains exceptional liquid asset reserves at 90.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Cardiol Therapeutics Inc Class A Industry Peers by Asset Resilience Ratio
Compare Cardiol Therapeutics Inc Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Vivesto AB
ST:VIVE |
Drug Manufacturers - Specialty & Generic | 17.16% |
|
CHRISTINA LAKE CANNABIS
F:CLB |
Drug Manufacturers - Specialty & Generic | 0.19% |
|
Turk Ilac ve Serum Sanayi AS
IS:TRILC |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Moberg Pharma AB (publ)
ST:MOB |
Drug Manufacturers - Specialty & Generic | 4.15% |
|
Canopy Growth Corp
NASDAQ:CGC |
Drug Manufacturers - Specialty & Generic | 0.45% |
|
Zhejiang Nhu Co Ltd
SHE:002001 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
CONSUN PHARMAC.GR.HD -10
F:C1P |
Drug Manufacturers - Specialty & Generic | 41.64% |
|
Aarey Drugs & Pharmaceuticals Limited
NSE:AAREYDRUGS |
Drug Manufacturers - Specialty & Generic | 0.34% |
Annual Asset Resilience Ratio for Cardiol Therapeutics Inc Class A (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Cardiol Therapeutics Inc Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 90.67% | CA$21.42 Million ≈ $15.49 Million |
CA$23.62 Million ≈ $17.09 Million |
-5.30pp |
| 2024-12-31 | 95.97% | CA$30.58 Million ≈ $22.12 Million |
CA$31.86 Million ≈ $23.05 Million |
+0.62pp |
| 2023-12-31 | 95.35% | CA$34.99 Million ≈ $25.31 Million |
CA$36.70 Million ≈ $26.55 Million |
-0.63pp |
| 2022-12-31 | 95.97% | CA$59.53 Million ≈ $43.06 Million |
CA$62.03 Million ≈ $44.87 Million |
+0.43pp |
| 2021-12-31 | 95.54% | CA$83.96 Million ≈ $60.74 Million |
CA$87.88 Million ≈ $63.57 Million |
+6.91pp |
| 2020-12-31 | 88.63% | CA$14.09 Million ≈ $10.19 Million |
CA$15.89 Million ≈ $11.50 Million |
+43.37pp |
| 2019-12-31 | 45.27% | CA$7.02 Million ≈ $5.08 Million |
CA$15.50 Million ≈ $11.21 Million |
-22.52pp |
| 2018-12-31 | 67.78% | CA$16.73 Million ≈ $12.10 Million |
CA$24.68 Million ≈ $17.86 Million |
-5.39pp |
| 2017-12-31 | 73.17% | CA$2.36 Million ≈ $1.70 Million |
CA$3.22 Million ≈ $2.33 Million |
-- |
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for… Read more